These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31388039)

  • 1. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.
    Pearsall RS; Davies MV; Cannell M; Li J; Widrick J; Mulivor AW; Wallner S; Troy ME; Spaits M; Liharska K; Sako D; Castonguay R; Keates S; Grinberg AV; Suragani RNVS; Kumar R
    Sci Rep; 2019 Aug; 9(1):11392. PubMed ID: 31388039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
    Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle.
    Castonguay R; Lachey J; Wallner S; Strand J; Liharska K; Watanabe AE; Cannell M; Davies MV; Sako D; Troy ME; Krishnan L; Mulivor AW; Li H; Keates S; Alexander MJ; Pearsall RS; Kumar R
    J Pharmacol Exp Ther; 2019 Mar; 368(3):435-445. PubMed ID: 30563942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
    Tsuchida K
    Acta Myol; 2008 Jul; 27(1):14-8. PubMed ID: 19108572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ.
    Lamar KM; Bogdanovich S; Gardner BB; Gao QQ; Miller T; Earley JU; Hadhazy M; Vo AH; Wren L; Molkentin JD; McNally EM
    PLoS Genet; 2016 May; 12(5):e1006019. PubMed ID: 27148972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
    Iskenderian A; Liu N; Deng Q; Huang Y; Shen C; Palmieri K; Crooker R; Lundberg D; Kastrapeli N; Pescatore B; Romashko A; Dumas J; Comeau R; Norton A; Pan J; Rong H; Derakhchan K; Ehmann DE
    Skelet Muscle; 2018 Oct; 8(1):34. PubMed ID: 30368252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
    Schneyer AL; Sidis Y; Gulati A; Sun JL; Keutmann H; Krasney PA
    Endocrinology; 2008 Sep; 149(9):4589-95. PubMed ID: 18535106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
    Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
    Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
    FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice.
    Rinaldi F; Zhang Y; Mondragon-Gonzalez R; Harvey J; Perlingeiro RCR
    Skelet Muscle; 2016; 6():21. PubMed ID: 27303621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of myostatin and follistatin in Mdx mice, an animal model for muscular dystrophy.
    Abe S; Soejima M; Iwanuma O; Saka H; Matsunaga S; Sakiyama K; Ide Y
    Zoolog Sci; 2009 May; 26(5):315-20. PubMed ID: 19715499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally acting ACE-083 increases muscle volume in healthy volunteers.
    Glasser CE; Gartner MR; Wilson D; Miller B; Sherman ML; Attie KM
    Muscle Nerve; 2018 Jun; 57(6):921-926. PubMed ID: 29486514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice.
    Lodberg A; van der Eerden BCJ; Boers-Sijmons B; Thomsen JS; Brüel A; van Leeuwen JPTM; Eijken M
    FASEB J; 2019 May; 33(5):6001-6010. PubMed ID: 30759349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.
    McCoy JC; Walker RG; Murray NH; Thompson TB
    J Biol Chem; 2019 Apr; 294(16):6333-6343. PubMed ID: 30814254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
    Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
    PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.
    Lee YS; Lehar A; Sebald S; Liu M; Swaggart KA; Talbot CC; Pytel P; Barton ER; McNally EM; Lee SJ
    Hum Mol Genet; 2015 Oct; 24(20):5711-9. PubMed ID: 26206886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.
    Suh J; Kim NK; Lee SH; Eom JH; Lee Y; Park JC; Woo KM; Baek JH; Kim JE; Ryoo HM; Lee SJ; Lee YS
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4910-4920. PubMed ID: 32071240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy.
    Nguyen HQ; Iskenderian A; Ehmann D; Jasper P; Zhang Z; Rong H; Welty D; Narayanan R
    CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):342-352. PubMed ID: 32419339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.